Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAPTURE: Rituximab in Sensitized Kidney Transplant
NCT00371904Phase 2Unknown
- Sponsor
- Hunter New England Health
- Start
- Apr 2006
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rituximab in kidney transplant rejection (2 arms), sponsored by Hunter New England Health. Primary endpoint: Biopsy proven antibody mediated rejection at 12 months. Status: unknown.
02
Drugs
rituximab
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT00371904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00371904.